Many studies have suggested that mutated K-ras is associated with a worse overall survival in patients with NSCLC [17]; anti-EGFR therapies are ineffective for K-ras mutant tumors [18,19], which are associated with lack of sensitivity and poorer clinical outcomes when treated with EGFR TKIs or chemotherapy [18,20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.